Genetic Modifying Factors of Cystic Fibrosis Phenotype: A Challenge for Modern Medicine

被引:28
作者
Butnariu, Lacramioara Ionela [1 ]
Tarca, Elena [2 ]
Cojocaru, Elena [3 ]
Rusu, Cristina [1 ]
Moisa, Stefana Maria [4 ]
Leon Constantin, Maria-Magdalena [5 ]
Gorduza, Eusebiu Vlad [1 ]
Trandafir, Laura Mihaela [4 ]
机构
[1] Grigore T Popa Univ Med & Pharm, Fac Med, Dept Med Genet, Iasi 700115, Romania
[2] Grigore T Popa Univ Med & Pharm, Dept Surg Pediat Surg 2, Iasi 700115, Romania
[3] Grigore T Popa Univ Med & Pharm, Dept Morphofunct Sci 1, Iasi 700115, Romania
[4] Grigore T Popa Univ Med & Pharm, Fac Med, Dept Mother & Child, Iasi 700115, Romania
[5] Grigore T Popa Univ Med & Pharm, Med Dept 1, Iasi 700115, Romania
关键词
cystic fibrosis; CFTR; modifier genes; phenotypic variability; GWAS; TRANSMEMBRANE CONDUCTANCE REGULATOR; LUNG-DISEASE SEVERITY; PSEUDOMONAS-AERUGINOSA INFECTION; MANNOSE-BINDING LECTIN; MODIFIER GENES; NITRIC-OXIDE; MECONIUM ILEUS; ALPHA(1)-ANTITRYPSIN DEFICIENCY; NUTRITIONAL-STATUS; CFTR;
D O I
10.3390/jcm10245821
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cystic fibrosis (CF) is a monogenic autosomal recessive disease caused by cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations. CF is characterized by a high phenotypic variability present even in patients with the same genotype. This is due to the intervention of modifier genes that interact with both the CFTR gene and environmental factors. The purpose of this review is to highlight the role of non-CFTR genetic factors (modifier genes) that contribute to phenotypic variability in CF. We analyzed literature data starting with candidate gene studies and continuing with extensive studies, such as genome-wide association studies (GWAS) and whole exome sequencing (WES). The results of both types of studies revealed that the number of modifier genes in CF patients is impressive. Their identification offers a new perspective on the pathophysiological mechanisms of the disease, paving the way for the understanding of other genetic disorders. In conclusion, in the future, genetic analysis, such as GWAS and WES, should be performed routinely. A challenge for future research is to integrate their results in the process of developing new classes of drugs, with a goal to improve the prognosis, increase life expectancy, and enhance quality of life among CF patients.
引用
收藏
页数:25
相关论文
共 130 条
[1]   Macrophage Migration Inhibitory Factor Enzymatic Activity, Lung Inflammation, and Cystic Fibrosis [J].
Adamali, Huzaifa ;
Armstrong, Michelle E. ;
McLaughlin, Anne Marie ;
Cooke, Gordon ;
McKone, Edward ;
Costello, Christine M. ;
Gallagher, Charles G. ;
Leng, Lin ;
Baugh, John A. ;
Fingerle-Rowson, Guenter ;
Bucala, Richard J. ;
McLoughlin, Paul ;
Donnelly, Seamas C. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (02) :162-169
[2]   Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits [J].
Aksit, Melis A. ;
Pace, Rhonda G. ;
Vecchio-Pagan, Briana ;
Ling, Hua ;
Rommens, Johanna M. ;
Boelle, Pierre-Yves ;
Guillot, Loic ;
Raraigh, Karen S. ;
Pugh, Elizabeth ;
Zhang, Peng ;
Strug, Lisa J. ;
Drumm, Mitch L. ;
Knowles, Michael R. ;
Cutting, Garry R. ;
Corvol, Harriet ;
Blackman, Scott M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (05)
[3]   CD14-dependent airway neutrophil response to inhaled LPS: Role of atopy [J].
Alexis, N ;
Eldridge, M ;
Reed, W ;
Bromberg, P ;
Peden, DB .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (01) :31-35
[4]  
[Anonymous], 2000, EUR J HUM GENET, V8, P998, DOI [10.1038/sj.ejhg.5200587, DOI 10.1038/SJ.EJHG.5200587]
[5]   TGF-β1 genotype and accelerated decline in lung function of patients with cystic fibrosis [J].
Arkwright, PD ;
Laurie, S ;
Super, M ;
Pravica, V ;
Schwarz, MJ ;
Webb, AK ;
Hutchinson, IV .
THORAX, 2000, 55 (06) :459-462
[6]   HLA-DR polymorphism in allergic bronchopulmonary aspergillosis [J].
Aron, Y ;
Bienvenu, T ;
Hubert, D ;
Dusser, D ;
Dall'Ava, J ;
Polla, BS .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 104 (04) :891-892
[7]   Tobacco smoke exposure limits the therapeutic benefit of tezacaf tor/ivacaf tor in pediatric patients with cystic fibrosis [J].
Baker, Elizabeth ;
Harris, William T. ;
Rowe, Steven M. ;
Rutland, Sarah B. ;
Oates, Gabriela R. .
JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (04) :612-617
[8]  
Baldan A, 2015, RHINOLOGY, V53, P359, DOI [10.4193/Rhin14.229, 10.4193/Rhino14.229]
[9]   MANAGEMENT OF ENDOCRINE DISEASE Cystic fibrosis-related diabetes: novel pathogenic insights opening new therapeutic avenues [J].
Barrio, Raquel .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (04) :R131-R141
[10]   The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status [J].
Bass, Rosara ;
Brownell, Jefferson N. ;
Stallings, Virginia A. .
NUTRIENTS, 2021, 13 (09)